Thrombospondin-1 receptor mediates autophagy of RAS-expressing cancer cells and triggers tumour growth inhibition

Anticancer Research

Volumn 33, Issue 4, 2013, Pages 1429-1438

  Kalas, Wojciech ^a   Swiderek, Ewelina ^a   Świtalska, Marta ^a   Wietrzyk, Joanna ^a   Rak, Janusz ^b   Strza̧dała, Leon ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

4N1K; Autophagy; Cancer; CD36; CD47; TSP 1

Indexed keywords

4N1K PEPTIDE; ACRIDINE ORANGE; ANTINEOPLASTIC AGENT; CASPASE 3; CD36 ANTIGEN; CD47 ANTIBODY; CD47 ANTIGEN; CELL ANTIBODY; PEPTIDE; RAS PROTEIN; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE DEPOLARIZATION; CELL PROLIFERATION; CELL TRANSFORMATION; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVATION; FEMALE; IMMUNOREACTIVITY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; STAINING;

ANIMALS; ANTIGENS, CD36; ANTIGENS, CD47; AUTOPHAGY; BLOTTING, WESTERN; CASPASE 3; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; GENES, RAS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; MUTATION; PEPTIDE FRAGMENTS; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84876771337     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Folkman J: Endogenous angiogenesis inhibitors. Apmis 112: 496-507, 2004. (Pubitemid 39626056)
2. Belotti D, Foglieni C, Resovi A, Giavazzi R and Taraboletti G: Targeting angiogenesis with compounds from the extracellular matrix. Int J Biochem Cell Biol 43: 1674-1685, 2011.
3. Watnick RS, Cheng Y-N, Rangarajan A, Ince TA and Weinberg RA: Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3: 219-231, 2003. (Pubitemid 37443878)
4. Kalas W, Yu JL, Milsom C, Rosenfeld J, Benezra R, Bornstein P and Rak J: Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras. Cancer Res 65: 8878-8886, 2005. (Pubitemid 41377377)
5. Dameron KM, Volpert OV, Tainsky MA and Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584, 1994. (Pubitemid 24308973)
6. Zabrenetzky V, Harris CC, Steeg PS and Roberts DD: Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 59: 191-195, 1994. (Pubitemid 24343361)
7. Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL and Bouck N: Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6: 41-48, 2000. (Pubitemid 30048524)
8. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J and Roberts DD: Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100: 1423-1431, 1999. (Pubitemid 29451703)
9. Lawler PR and Lawler J: Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med 2: a006627, 2012.
10. Yamauchi M, Imajoh-Ohmi S and Shibuya M: Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle. Cancer Sci 98: 1491-1497, 2007. (Pubitemid 47241775)
11. Zhang X and Lawler J: Thrombospondin-based antiangiogenic therapy. Microvasc Res 74: 90-99, 2009. (Pubitemid 350064284)
12. Rusk A, McKeegan E, Haviv F, Majest S, Henkin J and Khanna C: Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 12: 7444-7455, 2006. (Pubitemid 46095420)
13. Gordon MS, Mendelson D, Carr R, Knight RA, Humerickhouse RA, Iannone M and Stopeck AT: A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer 113: 3420-3429, 2008.
14. Yamauchi Y, Kuroki M, Imakiire T, Uno K, Abe H, Beppu R, Yamashita Y, Kuroki M and Shirakusa T: Opposite effects of thrombospondin-1 via CD36 and CD47 on homotypic aggregation of monocytic cells. Matrix Biol 21: 441-448, 2002. (Pubitemid 35286610)
15. Armant M, Avice MN, Hermann P, Rubio M, Kiniwa M, Delespesse G and Sarfati M: CD47 ligation selectively down-regulates human interleukin 12 production. J Exp Med 190: 1175-1182, 1999.
16. Brown EJ and Frazier WA: Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11: 130-135, 2001. (Pubitemid 32289443)
17. Lamy L, Ticchioni M, Rouquette-Jazdanian AK, Samson M, Deckert M, Greenberg AH and Bernard A: CD47 and the 19 kDa interacting protein-3 (BNIP3) in T cell apoptosis. J Biol Chem 278: 23915-23921, 2003. (Pubitemid 36830219)
18. Graf R, Freyberg M, Kaiser D and Friedl P: Mechanosensitive induction of apoptosis in fibroblasts is regulated by thrombospondin-1 and integrin associated protein (CD47). Apoptosis 7: 493-498, 2002. (Pubitemid 35334443)
19. Kalas W, Swiderek E, Rapak A, Kopij M, Rak J and Strzadala L: H-ras up-regulates expression of BNIP3. Anticancer Res 31: 2869-2875, 2011.
20. Mellor HR and Harris AL: The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Cancer Metastasis Rev 26: 553-566, 2007. (Pubitemid 350115110)
21. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, Domingo D and Yahalom J: A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 61: 439-444, 2001. (Pubitemid 32128593)
22. Kanzawa T, Kondo Y, Ito H, Kondo S and Germano I: Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 63: 2103-2108, 2003. (Pubitemid 36538613)
23. White E: Role of the metabolic stress responses of apoptosis and autophagy in tumor suppression. Ernst Schering Found Symp Proc pp. 23-34, 2007.
24. Pylayeva-Gupta Y, Grabocka E and Bar-Sagi D: RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11: 761-774, 2011.
25. Kalas W, Rybka J, Swiderek E, Ziolo E, Rybka W, Gamian A, Rak J and Strzadala L: H-Ras increases release of sphingosine resulting in down-regulation of TSP-1 in non-transformed cells. Int J Exp Pathol 93: 202-209, 2012.
26. Hanahan D and Weinberg RA: Hallmarks of Cancer: The Next Generation. Cell 144: 646-674, 2011.
27. McCormick F: Cancer therapy based on p53. Cancer J Sci Am 5: 139-144, 2009.
28. Lim MJ et al: Targeted therapy of DNA tumor virus-associated cancers using virus-activated transcription factors. Mol Ther 13: 899-909, 2006.
29. Weinstein IB and Joe A: Oncogene addiction. Cancer Res 68: 3077-3080; 2008.
30. Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22, 2003. (Pubitemid 37328883)
31. Shirasawa S, Furuse M, Yokoyama N and Sasazuki T: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85-88, 1993. (Pubitemid 23122749)
32. Rak JW, St Croix BD and Kerbel RS: Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 6: 3-18, 1995.
33. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K and Dvorak HF: Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5: 1041-1056, 1999. (Pubitemid 29233218)
34. Filleur S, Volpert OV, Degeorges A, Voland C, Reiher F, Clézardin P, Bouck N and Cabon F: In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev 15: 1373-1382, 2001. (Pubitemid 32524644)
35. Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J and Bouck NP: Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 55: 332-338, 1999. (Pubitemid 29076031)
36. Viloria-Petit A et al: Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J 22: 4091-4102, 2003. (Pubitemid 37021738)
37. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP and Campbell SC: Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 98: 682-689, 2002. (Pubitemid 34225618)
38. Mazure NM and Pouysségur J: Hypoxia-induced autophagy: cell death or cell survival? Curr Opin Cell Biol 22: 177-180, 2010.
39. Mathew R, Karantza-Wadsworth V, White E: Role of autophagy in cancer. Nat Rev Cancer 7: 961-967, 2007. (Pubitemid 350165856)
40. Jin S, DiPaola RS, Mathew R and White E: Metabolic catastrophe as a means to cancer cell death. J Cell Sci 120: 379-383, 2007. (Pubitemid 46332501)
41. Jin S and White E: Tumor suppression by autophagy through the management of metabolic stress. Autophagy 4: 563-566, 2008.
42. Martínez-Borra J and López-Larrea C: Autophagy and self-defense. Adv Exp Med Biol 738: 169-184, 2012.
43. Shen H-M and Codogno P: Autophagy is a survival force via suppression of necrotic cell death. Exp Cell Res 318: 1304-1308, 2012.